Third, the in vitro results regarding the antiangiogenic effect of JZL184 and 2-AG were confirmed at the in vivo level by demonstrating a tumor-regressive effect of JZL184 in association with a decrease in CD31-positive cells in xenografts from appropriately treated nude mice. Here, PECAM1 is linked to neoplasm.